Desk live·
ForensicPost
Ransomware/Regulation/File 25-1014b

Pharmaceutical Rules Govern Data Integrity but Barely Touch Network Security

Data integrity, trial conduct, record retention and manufacturing validation are exhaustively governed. Network security largely is not, and the two regimes barely touch.

Constructed geometry · not a chart of case data
TargetPharmaceutical sector
ActorRegulator
D. Kennedy12 min readConfidence: medium2 sources reviewed

Pharmaceutical companies operate under some of the most detailed regulation of any sector in this corpus. This file asks what it covers.

It Governs The Record And Not The Network

Data integrity requirements specify how records must be created, attributed, contemporaneous and unalterable. Trial conduct rules govern consent, protocol and reporting. Manufacturing validation governs the equipment and the process.

None of that is a security regime in the sense this database uses. It asks whether a record is trustworthy, not whether an adversary could reach the system holding it.

The corpus filed the same shape at 25-0601 for insurance — supervision attaching to solvency and conduct rather than to third-party platform security — and at 25-0720 for telecom, where subscriber identification rules produced bank-grade records under a communications regulator.

And The CRO Sits Outside Both

A contract research organisation is subject to trial conduct rules for the work it performs. Whether its corporate network is defensible is, per 25-0914b, not something this desk could establish that any regulator examines.

DORA at 25-0117 remains the one instrument in this corpus extending supervision to critical service providers, and it covers EU financial entities.

The Overlap That Does Exist Is Accidental And Useful

Data integrity rules require that records cannot be silently altered — which is, incidentally, an integrity control of exactly the kind 25-0921b argues nothing else in this corpus provides.

It is the aviation pattern at 25-0628 again: a regime built for safety producing a security property a security argument could not fund. Graded medium: this describes regulatory structure in general terms and no specific instrument has been reviewed.

This is an analysis file

It describes regulatory structure in general terms. It is not legal advice and no specific instrument has been reviewed by this desk. Corrections: corrections@forensicpost.com.

Sources
  1. Two biopharma breaches and the FDA warning behind themcentrexIT
  2. Cybersecurity in pharma: threats in 2025PharmaNow
D. Kennedy
Identity and access reporter. Former DFIR consultant. Signal on request.
// the chain of custody — tuesdays

Get the next file first.

One incident a week, taken apart properly. Logs, timelines, and what the filing left out.

PGP-signed edition · no tracking pixels · one-click unsubscribe
© 2026 ForensicPost Media · the desk · newsletter · searchGlossary